First general AIM Response to the European Commission Proposal on HTA

AIM understands the choice of the European Commission to focus its proposal on clinical effectiveness. The ultimate pricing and reimbursement decision is nevertheless not only based on clinical effectiveness, but also on (relative) cost-effectiveness. The Commission argues rightly that that decision should take country specific circumstances into consideration and AIM agrees with the Commission that it should remain a national competence. AIM sees nevertheless great added value in technical collaboration in this field. Non-clinical assessments remain difficult to make for individual Member States and inscrutable for the general public. It is important that countries are being supported in the strengthening of this part of the HTA process. Member States should give priority to collaboration in this field, in strengthening methodologies for (relative) cost-effectiveness studies and transparency of the pricing and reimbursement decision. Jointly developed methodologies should then be tailored to national contexts and priorities, also to ensure that Member States do not lose their independence on how to organize their healthcare system and how to allocate funds.

9 February 2018